Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma

We studied all patients at our institution with a diagnosis of multiple myeloma (MM), from 1 January 2004 to 1 July 2009, who received lenalidomide–dexamethasone (Rd) as initial therapy and had a time to progression of 72 months or longer. Of 240 patients, we identified 33 exceptional responders. Tw...

Descripción completa

Detalles Bibliográficos
Autores principales: Vu, T, Gonsalves, W, Kumar, S, Dispenzieri, A, Lacy, M Q, Buadi, F, Gertz, M A, Rajkumar, S V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635199/
https://www.ncbi.nlm.nih.gov/pubmed/26495860
http://dx.doi.org/10.1038/bcj.2015.91

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635199/
https://www.ncbi.nlm.nih.gov/pubmed/26495860
http://dx.doi.org/10.1038/bcj.2015.91

Ejemplares similares